Synlait Milk Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SMLKF research report →
Price Chart
About the company
Synlait Milk Limited, operating with its subsidiaries, manufactures and distributes an extensive range of dairy products across a global footprint, including China, various Asian territories, the Middle East, Africa, Australia, and its base in New Zealand. The company's operations encompass the processing, packaging, and marketing of these dairy offerings, which feature staples like cheese, butter, and different types of milk powder. Its comprehensive product portfolio further includes liquid milk, a variety of milk powder-based items, specialized nutritional products such as infant and adult formulas, bulk ingredients like skim milk powders and anhydrous milk fat, and unique nutritional components including lactoferrin.
- CEO
- Leon Fung
- IPO
- 2021
- Employees
- 560
- HQ
- Rakaia, CA, NZ
Get TickerSpark's AI analysis on SMLKF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $144.77M
- P/E
- -3.87
- Fwd P/E
- 7.87
- PEG
- 0.01
- P/S
- 0.17
- P/B
- 0.40
- EV/EBITDA
- -19.08
- Div Yield
- 0.00%
- Gross Margin
- 1.94%
- Op Margin
- -3.98%
- Net Margin
- -4.48%
- ROE
- -10.58%
- ROIC
- -6.19%
Latest fiscal year · YoY change
- Revenue
- $1.64B-10.2%
- Gross Profit
- $31.91M-69.7%
- Op Income
- $-65,266,235
- Net Income
- $-73,600,981-214.0%
- EPS
- $-0.12-175.9%
- OCF Growth
- -407.7%
- FCF Growth
- -268.2%
- 52W High
- $0.97
- 52W Low
- $0.24
- 50D MA
- $0.97
- 200D MA
- $0.97
- Beta
- 0.38
- RSI (14)
- 0
- Avg Volume
- 50.213
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Synlait said FY26 was financially difficult but showed a strong second-half operational recovery, with simpler operations after the North Island sale and confidence in backfilling lost volume over time.· September 27, 2026
- FY26 revenue was about $1.94 billion, reported EBITDA was $8.1 million, underlying EBITDA was $46.3 million, reported net loss after tax was $75.4 million, and underlying net loss after tax was $21.6 million.
- Second-half operating performance improved sharply: reported EBITDA improved by $77.5 million, underlying EBITDA by $38.1 million, reported NPAT by $85.8 million, and underlying NPAT by $33 million.
- Operational metrics recovered meaningfully, with manufactured-in-spec rising from 88% in FY25 to 93% in FY26 and production plan attainment increasing to 95.5%; August manufactured-in-spec was 99%.
- Net debt fell 14% to $215 million, helped by roughly $296 million of North Island sale proceeds, though operating cash flow remained negative $183.3 million due to working capital build.
- Management said the company will not give guidance for the five months ending 31 December 2026, but expects continued improvement in the second half run rate and a phased backfill of lost Advanced Nutrition volume over about three years.
FY26 group revenue increased to about $1.94 billion. Reported group EBITDA was $8.1 million and underlying group EBITDA was $46.3 million. Reported net loss after tax was $75.4 million and underlying net loss after tax was $21.6 million. Net debt reduced 14% to $215 million, while operating cash flow was negative $183.3 million. On the operating side, manufactured-in-spec improved from 88% in FY25 to 93% in FY26 and production plan attainment rose from nearly 92% to 95.5%. In the business mix, Consumer revenue increased 32% and Foodservice revenue increased 62%; Foodservice gross profit improved by $15.6 million to $11 million, while Advanced Nutrition revenue was broadly flat and gross profit declined 78%, and Ingredients revenue declined 15% with gross profit down 26%. Management highlighted a second-highest-ever milk price of $10.07 per kg of milk solids, including incentives. No forward guidance was given for the five months ending 31 December 2026, but management said the second-half run rate looked sustainable, the new Middle East customer could backfill 18% of FY27 capacity, and full backfill of the lost capacity is expected in about 3 years.
Leon Fung framed FY26 as a recovery year after a difficult first half, emphasizing that operations stabilized in the second half and that the business has now moved meaningfully through the ‘stabilize’ and ‘simplify’ phases of its recovery road map. He pointed to improved manufacturing reliability, stronger quality controls, leadership changes, and a broader revenue strategy as signs that the business is being reset for more resilient growth. His tone was cautious but upbeat, repeatedly saying the company is stronger, simpler, and better positioned for the future.
Andy Liu said the first-half weakness came from manufacturing plan adjustments, lower ingredients returns, and deferred tax assets, and that the main full-year drags were price/mix and especially costs, which reduced impact by $39.8 million. He noted SG&A contributed a $1.6 million benefit from tighter controls, while financing costs improved by $22.2 million due to better banking pricing, debt reduction after the North Island sale, and more cost-effective funding. He emphasized that cash remains the biggest challenge, with negative operating cash flow of $183.3 million driven by higher receivables and inventory, though the North Island sale generated roughly $296 million and helped bring net debt down to $215 million.
Analysts focused on whether the improved second-half run rate is sustainable, how much of the lost a2 English-label volume can be replaced, and whether the company can stay within bank covenants without near-term waivers. Management said it is confident the second-half improvement can continue, that the new Middle East customer and a broader pipeline should backfill volume over time, and that it is currently comfortable it will meet covenant compliance. They also said the company will review whether to reinstate guidance around early February, but not before then.
The positive case from the call is that Synlait appears to have fixed key operational problems, with manufacturing quality and plan attainment improving sharply and second-half EBITDA/NPAT recovering strongly. The North Island sale simplified the business, reduced debt, and management believes a new customer pipeline can replace lost volume while reducing reliance on any one customer or market.
The main risks are that FY26 still produced a net loss, operating cash flow was deeply negative, and working capital remained a major drag on the balance sheet. Management also acknowledged revenue concentration risk, the need to ramp new customers over 2-3 years, ongoing regulatory and quality costs, and that it is not giving near-term guidance for the next five months.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 76.9%
- Shares Outstanding
- 603.20M
- Float Shares
- 463.71M
Our SMLKF coverage
Recent articles, reports, and earnings notes.
No research on SMLKF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SMLKF report →Synlait Milk Limited (SMLKF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Sep 28
Synlait Milk Limited (SMLKF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Mar 22
Synlait Milk Limited (SMLKF) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.